| 1 |
35218068 | Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/-plerixafor. | 2022 Feb 26 |
1 |
| 2 |
33592119 | Stem cell mobilization in multiple myeloma patients relapsing after previous autologous hematopoietic stem cell transplantation: A multicenter report by the Polish Myeloma Study Group. | 2021 Jun |
2 |
| 3 |
33658647 | Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide. | 2021 Jul |
1 |
| 4 |
33911199 | The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft. | 2021 Sep |
1 |
| 5 |
34175195 | Cyclophosphamide plus etoposide is a safe and effective mobilization regimen in patients with multiple myeloma. | 2021 Oct |
3 |
| 6 |
34563457 | Addition of plerixafor for mobilization of stem cells with bortezomib is feasible in dialysis-dependent multiple myeloma. | 2021 Dec |
1 |
| 7 |
31631445 | Optimized peripheral blood progenitor cell mobilization for autologous hematopoietic cell transplantation in children with high-risk and refractory malignancies. | 2020 Feb |
1 |
| 8 |
32057615 | Mobilization kinetics of CD34+ hematopoietic stem cells stimulated by G-CSF and cyclophosphamide in patients with multiple sclerosis who receive an autotransplant. | 2020 Mar |
2 |
| 9 |
32298020 | Higher efficacy of intermediate dose cytarabine + G-CSF compared to cyclophosphamide + G-CSF in hematopoietic stem cell mobilization in patients with multiple myeloma. | 2020 Aug |
1 |
| 10 |
32499108 | A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis. | 2020 Oct |
3 |
| 11 |
33204611 | Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable cost. | 2020 |
1 |
| 12 |
30670057 | CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I/II clinical trial conducted in Japan. | 2019 Jan 22 |
1 |
| 13 |
26437056 | A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma. | 2016 Mar |
1 |
| 14 |
27334858 | Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization Capacity for Poorly Mobilized Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. | 2016 |
1 |
| 15 |
27863757 | Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen? | 2016 Oct - Dec |
1 |
| 16 |
25889496 | Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study. | 2015 Apr 17 |
1 |
| 17 |
24525280 | Peripheral blood CD34+ percentage at hematological recovery after chemotherapy is a good early predictor of harvest: a single-center experience. | 2014 May |
1 |
| 18 |
25005330 | ANCA-positive vasculitis as a secondary autoimmune disease after autologous stem cell transplantation for systemic sclerosis: a case report. | 2014 Nov-Dec |
1 |
| 19 |
23114516 | Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor. | 2013 Jan |
2 |
| 20 |
21894752 | [Optimization of mobilization regimes of blood hemopoietic stem cells in patients with multiple myeloma]. | 2011 |
4 |
| 21 |
19233728 | Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF. | 2009 Apr |
1 |
| 22 |
19899124 | Appropriate timing of G-CSF use after mobilization chemotherapy significantly increases the yield of CD34+ cells in autoPBSCT. | 2009 |
1 |
| 23 |
18608354 | The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma. | 2008 |
1 |
| 24 |
17763583 | Peripheral blood CD34+ cell mobilization in 42 patients with severe autoimmune disease. | 2007 Jun |
1 |
| 25 |
17825150 | [A prospective and randomized study of two conditioning regimens in treatment of severe systemic autoimmune diseases with autologous peripheral blood stem cell transplantation]. | 2007 Jun 26 |
1 |
| 26 |
16636524 | Successful autologous peripheral blood stem cell transplantation using thiotepa in a patient with systemic sclerosis and cardiac involvement. | 2006 May |
1 |
| 27 |
15133484 | High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity. | 2004 Jul |
1 |
| 28 |
15359655 | Guillain-Barré syndrome complicating mobilization therapy in a case of B-cell chronic lymphocytic leukemia. | 2004 Jul |
1 |
| 29 |
12651270 | CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. | 2003 Mar |
1 |
| 30 |
12732880 | G-CSF alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: results depend on degree of previous pretreatment. | 2003 May |
1 |
| 31 |
12853690 | Intermediate-dose cyclophosphamide and granulocyte colony-stimulating factor is a valid alternative to high-dose cyclophosphamide for mobilizing peripheral blood CD34+ cells in patients with multiple myeloma. | 2003 |
2 |
| 32 |
11346706 | Kinetics of PBPC mobilization by cyclophosphamide, as compared with that by epirubicin/paclitaxel followed by G-CSF support: implications for optimal timing of PBPC harvest. | 2001 May |
1 |
| 33 |
10954901 | GST-pi gene-transduced hematopoietic progenitor cell transplantation overcomes the bone marrow toxicity of cyclophosphamide in mice. | 2000 Aug 10 |
2 |
| 34 |
11007917 | Thrombopoietin and chemokine mRNA expression in patient post-chemotherapy and in vitro cytokine-treated marrow stromal cell layers. | 2000 |
1 |
| 35 |
10037025 | Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma. | 1999 Jan |
1 |
| 36 |
10455355 | Molecular remission in adult T cell leukemia after autologous CD34+ peripheral blood stem cell transplantation. | 1999 Jul |
1 |
| 37 |
10634173 | CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer. | 1999 Aug |
1 |
| 38 |
10951848 | [Autologous stem cell transplantation in a patient with juvenile chronic arthritis]. | 1999 Dec |
1 |
| 39 |
9535035 | Flow cytometry using annexin V can detect early apoptosis in peripheral blood stem cell harvests from patients with leukaemia and lymphoma. | 1998 Mar |
1 |
| 40 |
9543059 | CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF. | 1998 Mar |
1 |
| 41 |
9728932 | Leukapheresis products in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone. | 1998 Sep |
1 |
| 42 |
9894718 | PBSC mobilization, collection and positive selection in patients with chronic lymphocytic leukemia. | 1998 Dec |
1 |
| 43 |
9090787 | In vitro production of megakaryocytes from PIXY321 versus GM-CSF-mobilized peripheral blood progenitor cells. | 1997 |
2 |
| 44 |
9149745 | Steroid-refractory cutaneous graft-versus-host disease after transplantation of haploidentical parental CD34+ cells in children with Down's syndrome and recurrent acute leukemia. | 1997 Mar-Apr |
1 |
| 45 |
9163618 | Biological properties of peripheral blood progenitor cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor. | 1997 May |
1 |
| 46 |
9233591 | Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. | 1997 Jul |
1 |
| 47 |
9267668 | Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancer. | 1997 Jun |
1 |
| 48 |
9308634 | Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide, and granulocyte-colony-stimulating factor: an analysis of 497 patients. | 1997 Sep |
1 |
| 49 |
9382956 | Fibronectin fragment-facilitated retroviral transfer of the glutathione-S-transferase pi gene into CD34+ cells to protect them against alkylating agents. | 1997 Nov 1 |
2 |
| 50 |
8877715 | Improved priming for mobilization of and optimal timing for harvest of peripheral blood stem cells. | 1996 Aug |
2 |